Correction: Efficacy and safety of brolucizumab versus aflibercept in eyes with early persistent retinal fluid: 96-week outcomes from the HAWK and HARRIER studies

Author Department

Surgery

Document Type

Other

Publication Date

6-2022

PMID

35676464

Share

COinS